Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics, shared a post on LinkedIn:
“How to improve outcome in advanced ovarian epithelial cancer post 1st line chemotherapy and surgery?
Add IO or parp inhibitors or both or none ?
Money slide to summarize all 4 new trials in this space.
Taken from ASCO25.”
Read OncoDaily’s Special Articles from ASCO25:
Highlights from ASCO 2025 Day 1
Highlights from ASCO 2025 Day 2
Highlights from ASCO 2025 Day 3
Highlights from ASCO 2025 Day 4
